Article
Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to δ9-tetrahydrocannabinol

https://doi.org/10.1016/0091-3057(95)00023-PGet rights and content

Abstract

A brain constituent, the N-amide derivative of arachidonic acid, termed anandamide, has been recently proposed as a possible endogenous ligand for the cannabinoid receptor. The present study has been designed to examine whether the acute or chronic exposure to anandamide affected the binding of cannabinoid receptors in specific brain areas as occurred with the exogenous cannabinoid agonist, Δ9-tetrahydrocannabinol (THC). To this end, we measured the maximum binding capacity (Bmax) and the affinity (Kd) of cannabinoid receptors, by using [3H]CP-55,940 binding assays, in membranes obtained from several brain areas of male rats acutely or chronically treated with anandamide or THC. Results were as follows. The acute administration of either anandamide or THC increased the Bmax of cannabinoid receptors in the cerebellum and, particularly, in the hippocampus. This effect was also observed after 5 days of a daily exposure to either anandamide or THC. However, whereas the increase in the Bmax after the acute treatment seems to be caused by changes in the receptor affinity (high Kd), the increase after the chronic exposure may be attributed to an increase in the density of receptors. On the contrary, the [3H]CP-55,940 binding to cannabinoid receptors in the striatum, the limbic forebrain, the mesencephalon, and the medial basal hypothalamus was not altered after the acute exposure to anandamide or THC. However, the chronic exposure to THC significantly decreased the Bmax of these receptors in the striatum and nonsignificantly in the mesencephalon. This effect was not elicited after the chronic exposure to anandamide and was not accompanied by changes in the Kd. In summary, the response of cannabinoid receptors to the exposure to cannabinoid agonists varied depending on the brain region. Thus, there were brain areas, such as the hippocampus and the cerebellum, where [3H]CP-55,940 binding increased after the acute or chronic exposure to either anandamide or THC. Cannabinoid receptors were unaffected in other regions, such as the limbic forebrain and the medial basal hypothalamus, or downregulated in the striatum and slightly in the mesencephalon, but only after a chronic exposure to THC.

References (32)

  • T. Bridgen et al.

    Competitive inhibition of cannabinoid binding in a novel filtration assay

    FASEB J.

    (1990)
  • A. Bonnin et al.

    The acute effects of Δ9-tetrahydrocannabinol on the tuberoinfundibular dopaminergic activity, the anterior pituitary sensitivity to dopamine and the prolactin release vary as a function of estrous cycle

    Neuroendocrinology

    (1993)
  • W.A. Devane et al.

    Isolation and structure of a brain constituent that binds to the cannabinoid receptor

    Science

    (1992)
  • W.L. Dewey

    Cannabinoid pharmacology

    Pharmacol. Rev.

    (1986)
  • J.J. Fernández-Ruiz et al.

    Neuroendocrine effects of an acute dose of Δ9-tetrahydrocannabinol: changes in hypothalamic biogenic amines and anterior pituitary hormone secretion

    Neuroendocr. Lett.

    (1992)
  • J.J. Fernández-Ruiz et al.

    Maternal cannabinoid exposure and brain development: Changes in the ontogeny of dopaminergic neurons

  • Cited by (96)

    • Early-life stress exacerbates the effects of WIN55,212-2 and modulates the cannabinoid receptor type 1 expression

      2021, Neuropharmacology
      Citation Excerpt :

      Nevertheless, in the present study, the total number of CB1 immunorreactive cells in granular layer of cerebellum remained unaltered. Although we did not find changes in the number of CB1-positive Purkinje cells, we could not discard changes in the affinity of their binding sites (Romero et al., 1995). Contrasting with the results obtained before the antagonist injection, SR141716A injected animals show no differences in the number of CB1-positive Purkinje cells, which could indicate a possible compensatory mechanism that increases the number of CB1-positive cells in the cerebellum.

    • Endogenous and synthetic cannabinoids induce the downregulation of cannabinoid CB1 receptor in retina

      2019, Experimental Eye Research
      Citation Excerpt :

      Previous reports had suggested that subchronic/chronic administration of AEA produced differential adaptive changes in brain areas. In an earlier study in brain, it was shown that acute and chronic exposure to AEA led to differential effects in Bmax and Kd of [3H]CP-55,940 binding in different brain areas, none of which was the attenuation of receptor density (Romero et al., 1995). Rubino et al. (2000) reported that chronic administration of AEA reduced agonist stimulated [35S]-GTPγS in brain areas, yet downregulation of the receptor was not observed.

    • Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain

      2018, Neuropharmacology
      Citation Excerpt :

      In contrast, the acute WIN55,212-2 administration did not elicit any changes in CB1R binding sites in the aforementioned brain areas, proposing the existence of distinct regulatory mechanisms controlling CB1R adaptation after chronic and acute agonist treatment. Our results agree with previous studies demonstrating widespread desensitization of CB1R-mediated G-protein activation and down-regulation of CB1R binding after long-term, but not acute, administration of Δ9-THC, WIN55,212-2 or CP55,940 (Romero et al., 1995, 1997; Sim-Selley, 2003; Sim-Selley et al., 2006). Moreover, in the striatum and midbrain of regular marijuana users, CB1R binding capacity was reduced compared with non-users in postmortem human brains (Villares, 2007).

    • Reduced Brain Cannabinoid Receptor Availability in Schizophrenia

      2016, Biological Psychiatry
      Citation Excerpt :

      However, the authors reported an increase in CB1R only in the cerebellum, a finding that would be consistent with the findings of the current study. Nicotine does not appear to have a direct effect on CB1R but exposure to nicotine may alter eCB levels (58,59), and elevated eCBs, in turn, can alter CB1R binding capacity by enhancing affinity (acutely) and increasing receptor density (chronically) (60). Thus, it is conceivable that chronic tobacco smoking is associated with increased CB1R availability, as was observed in our study.

    • Cannabinoids and schizophrenia

      2015, Cannabinoids in Neurologic and Mental Disease
    View all citing articles on Scopus
    View full text